Total Payments
$470,926
2024 Payments
$36,599
Companies
19
Transactions
224
Medicare Patients
695
Medicare Billing
$725,876
Payment Breakdown by Category
Other$243,596 (51.7%)
Consulting$145,287 (30.9%)
Travel$50,425 (10.7%)
Research$26,831 (5.7%)
Food & Beverage$4,165 (0.9%)
Education$622.08 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $168,588 | 1 | 35.8% |
| Consulting Fee | $145,287 | 47 | 30.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $75,008 | 25 | 15.9% |
| Travel and Lodging | $50,425 | 71 | 10.7% |
| Unspecified | $26,831 | 20 | 5.7% |
| Food and Beverage | $4,165 | 57 | 0.9% |
| Education | $622.08 | 3 | 0.1% |
Payments by Type
General
$444,095
204 transactions
Research
$26,831
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $168,588 | 1 | $0 (2022) |
| Merck Sharp & Dohme LLC | $127,140 | 87 | $0 (2024) |
| F. Hoffmann-La Roche AG | $38,101 | 22 | $0 (2024) |
| Amgen Inc. | $31,407 | 26 | $0 (2024) |
| PFIZER INC. | $24,430 | 16 | $0 (2023) |
| Chugai Pharmaceutical Co., Ltd. | $21,409 | 12 | $0 (2022) |
| SANOFI US SERVICES INC. | $16,942 | 8 | $0 (2020) |
| Millennium Pharmaceuticals, Inc. | $10,591 | 6 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $8,446 | 23 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $5,000 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,599 | 19 | F. Hoffmann-La Roche AG ($21,948) |
| 2023 | $5,545 | 8 | PFIZER INC. ($3,810) |
| 2022 | $191,137 | 14 | E.R. Squibb & Sons, L.L.C. ($168,588) |
| 2021 | $13,740 | 6 | PFIZER INC. ($7,340) |
| 2020 | $29,495 | 15 | Merck Sharp & Dohme Corporation ($13,466) |
| 2019 | $59,065 | 41 | Merck Sharp & Dohme Corporation ($26,747) |
| 2018 | $59,835 | 50 | Merck Sharp & Dohme Corporation ($43,897) |
| 2017 | $75,510 | 71 | Merck Sharp & Dohme Corporation ($34,198) |
All Payment Transactions
224 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $8.70 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,220.00 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $36.04 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $8,232.00 | General |
| 09/05/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $2.88 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $242.54 | General |
| 08/08/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $242.54 | General |
| 08/08/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $212.05 | General |
| 08/08/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $58.98 | General |
| 07/12/2024 | Almirall LLC | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 03/06/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| 03/06/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $81.83 | General |
| 03/05/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $8,553.86 | General |
| 03/05/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $8,360.00 | General |
| 03/05/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $578.66 | General |
| 03/05/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $422.32 | General |
| 03/05/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $151.11 | General |
| 10/19/2023 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/19/2023 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB MULTI PRODUCT PF07265807 BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/09/2023 | PFIZER INC. | BRAFTOVI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 04/05/2023 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB MULTI PRODUCT PF07265807 BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/14/2023 | PFIZER INC. | BRAFTOVI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/13/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,960 | 4 |
| SASANLIMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,760 | 3 |
| GEDATOLISIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PROGNOSTIC SUBGROUPS FOR SURVIVAL AND TREATMENT EFFECTS IN BRAFV600-MUTATED METASTATIC MELANOMA POOLED ANALYSIS OF BRIM-2, BRIM-3, BRIM-7, AND COBRIM | F. Hoffmann-La Roche AG | $2,373 | 1 |
| ENCORAFENIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,930 | 4 |
| ENCORAFENIB MULTI PRODUCT PF07265807 BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | F. Hoffmann-La Roche AG | $1,522 | 3 |
| Melanoma subtypes that emerge during adaptive resistance to therapy are targets for bispecific T cell engager BiTE antibody constructs directed to CDH19 and DLL3 | Amgen Inc. | $6.11 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 246 | 14,751 | $3.4M | $663,734 |
| 2022 | 10 | 184 | 369 | $191,193 | $26,979 |
| 2021 | 8 | 148 | 262 | $127,191 | $18,836 |
| 2020 | 6 | 117 | 235 | $100,000 | $16,327 |
Total Patients
695
Total Services
15,617
Medicare Billing
$725,876
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 14,200 | $3.0M | $614,281 | 20.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 156 | $149,760 | $23,420 | 15.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 27 | 96 | $101,138 | $11,854 | 11.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 66 | $56,628 | $7,349 | 13.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 29 | $19,720 | $2,887 | 14.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 28 | $14,224 | $2,052 | 14.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 15 | 15 | $7,110 | $1,484 | 20.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 32 | 46 | $2,668 | $350.06 | 13.1% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 34 | 115 | $1,150 | $58.64 | 5.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 34 | 92 | $88,320 | $14,041 | 15.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 18 | 34 | $33,932 | $4,384 | 12.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 32 | $21,760 | $2,811 | 12.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 24 | $20,592 | $2,735 | 13.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 23 | 38 | $13,452 | $1,825 | 13.6% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2022 | 12 | 20 | $5,640 | $637.68 | 11.3% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2022 | 13 | 21 | $4,725 | $249.48 | 5.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 21 | 29 | $1,682 | $222.53 | 13.2% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2022 | 12 | 20 | $500.00 | $42.58 | 8.5% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2022 | 25 | 59 | $590.00 | $30.60 | 5.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 34 | 83 | $79,680 | $13,069 | 16.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 21 | 33 | $28,314 | $3,718 | 13.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 20 | 31 | $10,974 | $1,432 | 13.1% |
| 96361 | Hydration infusion into a vein | Office | 2021 | 12 | 25 | $5,625 | $320.25 | 5.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 20 | 26 | $1,508 | $202.02 | 13.4% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2021 | 12 | 18 | $450.00 | $39.59 | 8.8% |
About Dr. Antoni Ribas, MD
Dr. Antoni Ribas, MD is a Hematology & Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730109331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Antoni Ribas, MD has received a total of $470,926 in payments from pharmaceutical and medical device companies, with $36,599 received in 2024. These payments were reported across 224 transactions from 19 companies. The most common payment nature is "Grant" ($168,588).
As a Medicare-enrolled provider, Ribas has provided services to 695 Medicare beneficiaries, totaling 15,617 services with total Medicare billing of $725,876. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Los Angeles, CA
- Active Since 07/19/2006
- Last Updated 03/30/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1730109331
Products in Payments
- Non-Covered Product (Drug) $19,129
- Zelboraf (Biological) $16,153
- KEYTRUDA (Biological) $15,810
- NO PRODUCT DISCUSSED (Drug) $12,628
- BRAFTOVI (Drug) $11,162
- IMLYGIC (Biological) $4,000
- TAFINLAR (Drug) $3,788
- VENTANA RESEARCH & DEVELOPMENT (Device) $2,971
- MEKINIST (Drug) $2,167
- ADCETRIS (Biological) $1,125
- IMFINZI (Drug) $665.00
- MEKTOVI (Drug) $620.00
- PDR001 (Drug) $16.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Los Angeles
Dennis Slamon, Md, MD
Hematology & Oncology — Payments: $4.3M
Hematology & Oncology $4.3M
George Yaghmour
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Robert Vescio, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Kevin Kelly, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
David Berz, Md, Phd, Mph, MD, PHD, MPH
Hematology & Oncology — Payments: $613,380
Hematology & Oncology $613,380
Raghuveer Ranganathan, M.d, M.D
Hematology & Oncology — Payments: $472,334
Hematology & Oncology $472,334